Development of the Crohn's disease digestive damage score, the Lemann score.

Development of the Crohn's disease digestive damage score, the Lemann score.

Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An instrument to measure cumulative structural damage to the bowel, which may predict long-term disability, is needed. The aim of this article...

Detaylı Bibliyografya
Asıl Yazarlar:	Pariente, B, Cosnes, J, Danese, S, Sandborn, W, Lewin, M, Fletcher, J, Chowers, Y, D'Haens, G, Feagan, BG, Hibi, T, Hommes, D, Irvine, E, Kamm, M, Loftus, E, Louis, E, Michetti, P, Munkholm, P, Oresland, T, Panés, J, Peyrin-Biroulet, L, Reinisch, W, Sands, B, Schoelmerich, J, Schreiber, S, Tilg, H
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2011

Benzer Materyaller

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
Yazar:: Sandborn, W, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
Yazar:: Peyrin-Biroulet, L, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
Yazar:: Danese, S, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
Yazar:: D'Haens, G, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
Yazar:: Khanna, R, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Juan Lémann Cazabón (1928-1998)
Yazar:: Luis Merino
Baskı/Yayın Bilgisi: (1998-07-01)

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Yazar:: Peyrin-Biroulet, L, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
Yazar:: Remo Panaccione, ve diğerleri
Baskı/Yayın Bilgisi: (2015-12-01)

Modified Mayo score Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
Yazar:: William J. Sandborn, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Evolving concepts in phases I and II drug development for Crohn's Disease
Yazar:: Jairath, V, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
Yazar:: Miquel Marquès Camí, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
Yazar:: Jairath, V, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
Yazar:: Reinisch, W, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
Yazar:: Sandborn, W, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

European evidence-based Consensus on the management of ulcerative colitis: Current management.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn’s disease, based on the Lémann index
Yazar:: Mingming Zhu, ve diğerleri
Baskı/Yayın Bilgisi: (2020-12-01)

Review article: defining remission in ulcerative colitis.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?
Yazar:: Fabio Vieira TEIXEIRA, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Can we change the natural course of inflammatory bowel disease?
Yazar:: Catherine Le Berre, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Development of an index to define overall disease severity in IBD
Yazar:: Siegel, C, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
Yazar:: Vuitton, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
Yazar:: Napolitano M, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Yazar:: D'Haens, G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Biosimilars in IBD: hope or expectation?
Yazar:: Gecse, K, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

“Dramatische taalvaardigheid” and how to remediate it - Developing and evaluating a remedial writing programme in a Dutch-medium secondary school
Yazar:: D'Haens, A
Baskı/Yayın Bilgisi: (2020)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
Yazar:: Lichtenstein, G, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved]
Yazar:: Daniele Piovani, ve diğerleri
Baskı/Yayın Bilgisi: (2020-05-01)

O GRUPO LEMANN E O NOVO PAPEL DOS APARELHOS PRIVADOS DE HEGEMONIA NO CAMPO DA EDUCAÇÃO NO BRASIL
Yazar:: Maria Teresa Cavalcanti de Oliveira
Baskı/Yayın Bilgisi: (2019-12-01)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Yazar:: Colombel, J, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
Yazar:: Diogo Magalhaes, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
Yazar:: Gasche, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española)
Yazar:: A. Dignass, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.
Yazar:: Dignass, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
Yazar:: Travis, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)